Ad
related to: moderna covid-19 vaccine (spikevax)
Search results
Moderna says new-generation COVID vaccine more effective than Spikevax
Market Watch· 6 days agosaid Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed...
Moderna’s next-gen COVID vaccine shows non-inferiority to its current shot
WSAU Wausau· 5 days ago(Reuters) -Moderna said on Thursday its next-generation COVID-19 vaccine candidate met its main goal...
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial
Clinical Trials Arena via Yahoo Finance· 5 days agoModerna has announced that its Phase III clinical trial of the investigational next-generation Covid...
Moderna announces positive Phase III data for Covid-19/Influenza mRNA vaccine
Clinical Trials Arena via Yahoo Finance· 6 days agoCovid-19 vaccine candidate. At this time, mRNA-1083 is poised to be the first Covid-19/influenza ...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-...
Morningstar· 6 days ago(NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its primary ...
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines | Investing.com
Investing.com· 1 day agoStocks Analysis by MarketBeat.com (Jea Yu) covering: Merck & Company Inc, Amgen Inc, Biogen Inc,...
Moderna says next-gen COVID shot effective in study
BioPharma Dive via Yahoo Finance· 6 days agoTrial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases...
Moderna Just Gave Investors Another Reason to Buy the Stock | The Motley Fool
The Motley Fool· 2 days agoModerna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. Let's look...
Moderna's mRNA-1283 vaccine shows promise in Phase 3 trial By Investing.com
Investing.com· 5 days agoModerna , Inc. (NASDAQ:MRNA) has announced successful results from the Phase 3 trial of its...
Gateway - Quartz
Quartz· 5 hours agoNovo Nordisk responded this week to the Federal Trade Commission’s (FTC) suggestion that it filed ‘junk’ patents to prevent competition and raise prices. Moderna stock surged ...
